Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important Principles

By using the website www.bellevue-am.uk, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

For a full explanation of risks and the overall risk profile of financial products mentioned on this site, please refer to the relevant Key Investor Information Documents (KIIDs) and Prospectuses.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. Alternatively, you can select "I don't accept" if you wish to leave the website.

Our Offering

Healthcare – a world full of opportunities
Bellevue has identified very compelling special themes within the healthcare industry that are backed by structural growth trends. A key growth driver is an aging society and the diseases and conditions that afflict the elderly. Meanwhile the growing Westernization of modern lifestyles has long been a reality and will become even more apparent in the decades to come. This trend explains the rise of many of today's chronic diseases. There are now more than 400 million people with diabetes worldwide, for example, and the trend is still pointing up. Innovative drugs and new forms of treatment are needed to contain the sharply rising cost of healthcare. Many investors still think of a classic pharmaceutical company when they hear the word “healthcare”, but the healthcare sector actually offers a much wider selection of investment opportunities than just pharma. The professionals at Bellevue actively cover and capture the most promising of these opportunities.

Bellevue Healthcare – a differentiated approach for the rapidly evolving healthcare paradigm

It is widely appreciated that the demographic drivers of healthcare consumption are inexorable; it is the secular growth story of our age. Nonetheless, the philosophy of Bellevue Healthcare emerged from the realisation that healthcare in the wider sense can, and indeed must change because it is broken and no longer fit for purpose to serve the needs of an ageing population burdened with chronic (i.e. incurable) conditions that will need to be managed for the rest of these patients’ lives.

  • Technology-led revolution in the care paradigm

    open glightbox

    Technology-led revolution in the care paradigm

    This change will be profound; a technology-led revolution in the care paradigm and Bellevue wanted to have a complimentary strategy to sit alongside its other funds and capitalise on this exciting opportunity. Such a notion is all well and good, but it is hardly a revelation; one need not search far and wide to find an article about the failings of the healthcare system in whatever country you are residing in.

  • Our needs-based access to the healthcare growth market

    open glightbox

    Our needs-based access to the healthcare growth market

    So what is our approach to turn this idea into a practicable investment framework? We have identified a number of areas ripe for profound change within the existing care continuum, where the opportunity to revolutionise care delivery has been made possible by the emergence of a number of new products and services that one can gain exposure to through a public equity strategy. We offer access to this attractive growth market through an open ended and a closed ended fund according to your needs.

BB Biotech – the access to fast growing biotechnology companies

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than 25 years of experience. The shares of BB Biotech are listed on the SIX Swiss Exchange, the Frankfurt Stock Exchange and the Stock Exchange in Milan. Its investments are focused on listed companies that are developing and commercializing novel drugs that offer sound value for the healthcare system.

  • Crown jewel of the biotech industry in a diversified portfolio

    open glightbox

    Crown jewel of the biotech industry in a diversified portfolio

    Our decades of expertise combined with a systematic strategy and clear focus have made us one of the world’s largest investors in the biotech sector. BB Biotech’s success is driven by its underlying investment portfolio. Its seasoned and highly specialized Investment Team constructs a concentrated and balanced portfolio comprised of 20 to 35 positions. Most of the stocks in the portfolio are innovative mid and small caps, crown jewels of the biotech industry with distinct profiles and high growth potential. 

  • Experienced biotech specialists with long standing track record

    open glightbox

    Experienced biotech specialists with long standing track record

    The Investment Management Team of Bellevue Asset Management AG has extensive academic knowledge in the areas of biochemistry, molecular biology, medicine and economics. In the strategic decisions and analysis of portfolio investments, the team is guided by the decades of collective experience of the distinguished Board of Directors.